GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

Some 20 weeks after stopping their drugs, the participants in the studies had put back on an average of 2.5 kilograms (5.5 ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

Modern weight loss medications represent a breakthrough, but they are most effective when combined with the right lifestyle ...

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

A new weight-loss drug promises to offer powerful results for Americans struggling with obesity, potentially surpassing the success patients have seen with Ozempic and Wegovy.. Zepbound, which was ...